Antithrombin-III

Phase 2Small molecule

Octapharma

Antithrombin-III is one of 128 small molecule programs targeting Ischemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

Infectious DiseaseActive, not recruiting

Portal Vein ThrombosisActive, not recruiting

Acute Kidney InjuryActive, not recruiting

COVID-19Active, not recruiting

IschemiaPhase 2

Active, not recruiting

Infectious DiseasePhase 2

Active, not recruiting

Portal Vein ThrombosisPhase 1

Active, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Antithrombin-III

Octapharma

Phase 2

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Statin

Bristol-Myers Squibb

Preclinical

1 4

Nadroparin

GSK

Preclinical

1 5

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Conventional

PPopulation Health Research Institute

Preclinical

1 7

Exoflo

DDirect Biologics, LLC

Preclinical

3 8

Moderna COVID-19 Vaccine

Moderna

Preclinical

4 9

COVID-19 Vaccines

UUniversity of British Columbia

Preclinical

10 10

Hydroxychloroquine Pill

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiopulmonary Bypass3 trials

Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery

Completed·TThe Hospital for Sick Children·Phase 3·NCT01530737·18 enrolled

Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass

Completed·IInstituto Grifols, S.A.·Phase 2·NCT00823082·200 enrolled

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

Terminated·UUniversity of Rochester·Phase 1·NCT01698567·6 enrolled

Ischemia1 trial

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT02251041·143 enrolled

COVID-191 trial

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

Completed· Octapharma logo

Octapharma··NCT04651400·300 enrolled

Portal vein thrombosis1 trial

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

Withdrawn·JJonathan Stine·Phase 1·NCT04055389

Acute Kidney Injury1 trial

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

Completed·—··NCT04912193·2,395 enrolled

3 more indications

Infectious Disease1 trial

Antithrombin III in Infectious Disease Caused by COVID-19

Terminated·EEnrique Ginzburg·Phase 2·NCT04899232·52 enrolled

After Cardiac Surgery1 trial

Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery

Unknown status·UUniversity of Bari·Phase 4·NCT01201070·90 enrolled

Infants1 trial

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

Completed·—·Phase 1·NCT02631174·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Antithrombin-III. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antithrombin-III compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antithrombin-III. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Octapharma

Antithrombin-III

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiopulmonary Bypass3 trials

Ischemia1 trial

COVID-191 trial

Portal vein thrombosis1 trial

Acute Kidney Injury1 trial

Infectious Disease1 trial

After Cardiac Surgery1 trial

Infants1 trial

References

Drug Info

Quick Facts

Related News